Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B

Valdimara C. Vieira, Brandon Leonard, Elizabeth A. White, Gabriel J. Starrett, Nuri A. Temiz, Laurel D. Lorenz, Denis Lee, Marcelo A. Soares, Paul F. Lambert, Peter M. Howley, Reuben S. Harris

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Several recent studies have converged upon the innate immune DNA cytosine deaminase APOBEC3B (A3B) as a significant source of genomic uracil lesions and mutagenesis in multiple human cancers, including those of the breast, head/neck, cervix, bladder, lung, ovary, and other tissues. A3B is upregulated in these tumor types relative to normal tissues, but the mechanism is unclear. Because A3B also has antiviral activity in multiple systems and is a member of the broader innate immune response, we tested the hypothesis that human papillomavirus (HPV) infection causes A3B upregulation. We found that A3B mRNA expression and enzymatic activity were upregulated following transfection of a high-risk HPV genome and that this effect was abrogated by inactivation of E6. Transduction experiments showed that the E6 oncoprotein alone was sufficient to cause A3B upregulation, and a panel of high-risk E6 proteins triggered higher A3B levels than did a panel of low-risk or noncancer E6 proteins. Knockdown experiments in HPV-positive cell lines showed that endogenous E6 is required for A3B upregulation. Analyses of publicly available head/neck cancer data further support this relationship, as A3B levels are higher in HPV-positive cancers than in HPV-negative cancers. Taken together with the established role for high-risk E6 in functional inactivation of TP53 and published positive correlations in breast cancer between A3B upregulation and genetic inactivation of TP53, our studies suggest a model in which high-risk HPV E6, possibly through functional inactivation of TP53, causes derepression of A3B gene transcription. This would lead to a mutator phenotype that explains the observed cytosine mutation biases in HPV-positive head/neck and cervical cancers.

Original languageEnglish (US)
Article numbere02234-14
JournalmBio
Volume5
Issue number6
DOIs
StatePublished - Dec 23 2014

Fingerprint

Antiviral Agents
Up-Regulation
DNA
Neoplasms
Head and Neck Neoplasms
Cytosine Deaminase
Papillomavirus Infections
Uracil
Oncogene Proteins
Cytosine
Human Genome
Innate Immunity
Cervix Uteri
Mutagenesis
Uterine Cervical Neoplasms
Transfection
Ovary
Urinary Bladder
Proteins
Breast

Cite this

Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B. / Vieira, Valdimara C.; Leonard, Brandon; White, Elizabeth A.; Starrett, Gabriel J.; Temiz, Nuri A.; Lorenz, Laurel D.; Lee, Denis; Soares, Marcelo A.; Lambert, Paul F.; Howley, Peter M.; Harris, Reuben S.

In: mBio, Vol. 5, No. 6, e02234-14, 23.12.2014.

Research output: Contribution to journalArticle

Vieira, VC, Leonard, B, White, EA, Starrett, GJ, Temiz, NA, Lorenz, LD, Lee, D, Soares, MA, Lambert, PF, Howley, PM & Harris, RS 2014, 'Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B', mBio, vol. 5, no. 6, e02234-14. https://doi.org/10.1128/mBio.02234-14
Vieira, Valdimara C. ; Leonard, Brandon ; White, Elizabeth A. ; Starrett, Gabriel J. ; Temiz, Nuri A. ; Lorenz, Laurel D. ; Lee, Denis ; Soares, Marcelo A. ; Lambert, Paul F. ; Howley, Peter M. ; Harris, Reuben S. / Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B. In: mBio. 2014 ; Vol. 5, No. 6.
@article{285ac0974f6f431da0724cacb0aee981,
title = "Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B",
abstract = "Several recent studies have converged upon the innate immune DNA cytosine deaminase APOBEC3B (A3B) as a significant source of genomic uracil lesions and mutagenesis in multiple human cancers, including those of the breast, head/neck, cervix, bladder, lung, ovary, and other tissues. A3B is upregulated in these tumor types relative to normal tissues, but the mechanism is unclear. Because A3B also has antiviral activity in multiple systems and is a member of the broader innate immune response, we tested the hypothesis that human papillomavirus (HPV) infection causes A3B upregulation. We found that A3B mRNA expression and enzymatic activity were upregulated following transfection of a high-risk HPV genome and that this effect was abrogated by inactivation of E6. Transduction experiments showed that the E6 oncoprotein alone was sufficient to cause A3B upregulation, and a panel of high-risk E6 proteins triggered higher A3B levels than did a panel of low-risk or noncancer E6 proteins. Knockdown experiments in HPV-positive cell lines showed that endogenous E6 is required for A3B upregulation. Analyses of publicly available head/neck cancer data further support this relationship, as A3B levels are higher in HPV-positive cancers than in HPV-negative cancers. Taken together with the established role for high-risk E6 in functional inactivation of TP53 and published positive correlations in breast cancer between A3B upregulation and genetic inactivation of TP53, our studies suggest a model in which high-risk HPV E6, possibly through functional inactivation of TP53, causes derepression of A3B gene transcription. This would lead to a mutator phenotype that explains the observed cytosine mutation biases in HPV-positive head/neck and cervical cancers.",
author = "Vieira, {Valdimara C.} and Brandon Leonard and White, {Elizabeth A.} and Starrett, {Gabriel J.} and Temiz, {Nuri A.} and Lorenz, {Laurel D.} and Denis Lee and Soares, {Marcelo A.} and Lambert, {Paul F.} and Howley, {Peter M.} and Harris, {Reuben S.}",
year = "2014",
month = "12",
day = "23",
doi = "10.1128/mBio.02234-14",
language = "English (US)",
volume = "5",
journal = "mBio",
issn = "2161-2129",
publisher = "American Society for Microbiology",
number = "6",

}

TY - JOUR

T1 - Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B

AU - Vieira, Valdimara C.

AU - Leonard, Brandon

AU - White, Elizabeth A.

AU - Starrett, Gabriel J.

AU - Temiz, Nuri A.

AU - Lorenz, Laurel D.

AU - Lee, Denis

AU - Soares, Marcelo A.

AU - Lambert, Paul F.

AU - Howley, Peter M.

AU - Harris, Reuben S.

PY - 2014/12/23

Y1 - 2014/12/23

N2 - Several recent studies have converged upon the innate immune DNA cytosine deaminase APOBEC3B (A3B) as a significant source of genomic uracil lesions and mutagenesis in multiple human cancers, including those of the breast, head/neck, cervix, bladder, lung, ovary, and other tissues. A3B is upregulated in these tumor types relative to normal tissues, but the mechanism is unclear. Because A3B also has antiviral activity in multiple systems and is a member of the broader innate immune response, we tested the hypothesis that human papillomavirus (HPV) infection causes A3B upregulation. We found that A3B mRNA expression and enzymatic activity were upregulated following transfection of a high-risk HPV genome and that this effect was abrogated by inactivation of E6. Transduction experiments showed that the E6 oncoprotein alone was sufficient to cause A3B upregulation, and a panel of high-risk E6 proteins triggered higher A3B levels than did a panel of low-risk or noncancer E6 proteins. Knockdown experiments in HPV-positive cell lines showed that endogenous E6 is required for A3B upregulation. Analyses of publicly available head/neck cancer data further support this relationship, as A3B levels are higher in HPV-positive cancers than in HPV-negative cancers. Taken together with the established role for high-risk E6 in functional inactivation of TP53 and published positive correlations in breast cancer between A3B upregulation and genetic inactivation of TP53, our studies suggest a model in which high-risk HPV E6, possibly through functional inactivation of TP53, causes derepression of A3B gene transcription. This would lead to a mutator phenotype that explains the observed cytosine mutation biases in HPV-positive head/neck and cervical cancers.

AB - Several recent studies have converged upon the innate immune DNA cytosine deaminase APOBEC3B (A3B) as a significant source of genomic uracil lesions and mutagenesis in multiple human cancers, including those of the breast, head/neck, cervix, bladder, lung, ovary, and other tissues. A3B is upregulated in these tumor types relative to normal tissues, but the mechanism is unclear. Because A3B also has antiviral activity in multiple systems and is a member of the broader innate immune response, we tested the hypothesis that human papillomavirus (HPV) infection causes A3B upregulation. We found that A3B mRNA expression and enzymatic activity were upregulated following transfection of a high-risk HPV genome and that this effect was abrogated by inactivation of E6. Transduction experiments showed that the E6 oncoprotein alone was sufficient to cause A3B upregulation, and a panel of high-risk E6 proteins triggered higher A3B levels than did a panel of low-risk or noncancer E6 proteins. Knockdown experiments in HPV-positive cell lines showed that endogenous E6 is required for A3B upregulation. Analyses of publicly available head/neck cancer data further support this relationship, as A3B levels are higher in HPV-positive cancers than in HPV-negative cancers. Taken together with the established role for high-risk E6 in functional inactivation of TP53 and published positive correlations in breast cancer between A3B upregulation and genetic inactivation of TP53, our studies suggest a model in which high-risk HPV E6, possibly through functional inactivation of TP53, causes derepression of A3B gene transcription. This would lead to a mutator phenotype that explains the observed cytosine mutation biases in HPV-positive head/neck and cervical cancers.

UR - http://www.scopus.com/inward/record.url?scp=84920969941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920969941&partnerID=8YFLogxK

U2 - 10.1128/mBio.02234-14

DO - 10.1128/mBio.02234-14

M3 - Article

C2 - 25538195

AN - SCOPUS:84920969941

VL - 5

JO - mBio

JF - mBio

SN - 2161-2129

IS - 6

M1 - e02234-14

ER -